Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna W G, Byhardt R
Wayne State University, Detroit, MI 48201, USA.
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51. doi: 10.1016/s0360-3016(96)00619-0.
Promising results from new approaches such as radiosurgery or stereotactic surgery of brain metastases have recently been reported. Are these results due to the therapy alone or can the results be attributed in part to patient selection? An analysis of tumor/patient characteristics and treatment variables in previous Radiation Therapy Oncology Group (RTOG) brain metastases studies was considered necessary to fully evaluate the benefit of these new interventions.
The database included 1200 patients from three consecutive RTOG trials conducted between 1979 and 1993, which tested several different dose fractionation schemes and radiation sensitizers. Using recursive partitioning analysis (RPA), a statistical methodology which creates a regression tree according to prognostic significance, eighteen pretreatment characteristics and three treatment-related variables were analyzed.
According to the RPA tree the best survival (median: 7.1 months) was observed in patients < 65 years of age with a Karnofsky Performance Status (KPS) of at least 70, and a controlled primary tumor with the brain the only site of metastases. The worst survival (median: 2.3 months) was seen in patients with a KPS less than 70. All other patients had relatively minor differences in observed survival, with a median of 4.2 months.
Based on this analysis, we suggest the following three classes: Class 1: patients with KPS > or = 70, < 65 years of age with controlled primary and no extracranial metastases; Class 3: KPS < 70; Class 2- all others. Using these classes or stages, new treatment techniques can be tested on homogeneous patient groups.
最近有报道称,诸如脑转移瘤的放射外科手术或立体定向手术等新方法取得了令人鼓舞的成果。这些结果仅仅是由于治疗本身,还是部分可归因于患者的选择?为了全面评估这些新干预措施的益处,有必要对先前放射治疗肿瘤学组(RTOG)脑转移瘤研究中的肿瘤/患者特征及治疗变量进行分析。
数据库纳入了1979年至1993年间连续开展的三项RTOG试验中的1200例患者,这些试验测试了几种不同的剂量分割方案和放射增敏剂。使用递归划分分析(RPA)这一根据预后意义创建回归树的统计方法,对18项治疗前特征和3项与治疗相关的变量进行了分析。
根据RPA树,在年龄<65岁、卡氏功能状态(KPS)至少为70、原发肿瘤得到控制且脑为唯一转移部位的患者中观察到最佳生存情况(中位生存期:7.1个月)。KPS低于70的患者生存情况最差(中位生存期:2.3个月)。所有其他患者的观察生存情况差异相对较小,中位生存期为4.2个月。
基于该分析,我们建议分为以下三类:1类:KPS≥70、年龄<65岁、原发肿瘤得到控制且无颅外转移的患者;3类:KPS<70;2类:所有其他患者。利用这些类别或阶段,可以在同质患者群体中测试新的治疗技术。